CN112869169B - 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 - Google Patents
副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 Download PDFInfo
- Publication number
- CN112869169B CN112869169B CN202011369708.6A CN202011369708A CN112869169B CN 112869169 B CN112869169 B CN 112869169B CN 202011369708 A CN202011369708 A CN 202011369708A CN 112869169 B CN112869169 B CN 112869169B
- Authority
- CN
- China
- Prior art keywords
- lactobacillus paracasei
- intestinal
- immunity
- cfu
- etec
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 241000186605 Lactobacillus paracasei Species 0.000 title claims abstract description 67
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 20
- 230000008944 intestinal immunity Effects 0.000 title claims abstract description 11
- 208000035143 Bacterial infection Diseases 0.000 title abstract description 5
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 19
- 238000004321 preservation Methods 0.000 claims abstract description 11
- 108090001007 Interleukin-8 Proteins 0.000 claims description 10
- 230000000688 enterotoxigenic effect Effects 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 241001302580 Escherichia coli ETEC H10407 Species 0.000 claims description 2
- 244000052616 bacterial pathogen Species 0.000 abstract description 12
- 241000894006 Bacteria Species 0.000 abstract description 8
- 206010012735 Diarrhoea Diseases 0.000 abstract description 5
- 208000015181 infectious disease Diseases 0.000 abstract description 5
- 230000009545 invasion Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 31
- 241000588724 Escherichia coli Species 0.000 description 25
- 230000000694 effects Effects 0.000 description 15
- 230000001717 pathogenic effect Effects 0.000 description 14
- 238000012360 testing method Methods 0.000 description 12
- 244000052769 pathogen Species 0.000 description 10
- 102000004890 Interleukin-8 Human genes 0.000 description 9
- 230000000369 enteropathogenic effect Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 230000004888 barrier function Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- 235000013361 beverage Nutrition 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 235000015140 cultured milk Nutrition 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 210000004251 human milk Anatomy 0.000 description 3
- 235000020256 human milk Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000005027 intestinal barrier Anatomy 0.000 description 3
- 230000007358 intestinal barrier function Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 238000009629 microbiological culture Methods 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 150000002482 oligosaccharides Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061126 Escherichia infection Diseases 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 230000005353 IP-10 production Effects 0.000 description 1
- 208000019637 Infantile Diarrhea Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 101100314144 Mus musculus Tnip1 gene Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- 208000020612 escherichia coli infection Diseases 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 235000021001 fermented dairy product Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 210000005026 intestinal epithelial barrier Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- WRUGWIBCXHJTDG-UHFFFAOYSA-L magnesium sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Mg+2].[O-]S([O-])(=O)=O WRUGWIBCXHJTDG-UHFFFAOYSA-L 0.000 description 1
- 229940061634 magnesium sulfate heptahydrate Drugs 0.000 description 1
- CDUFCUKTJFSWPL-UHFFFAOYSA-L manganese(II) sulfate tetrahydrate Chemical compound O.O.O.O.[Mn+2].[O-]S([O-])(=O)=O CDUFCUKTJFSWPL-UHFFFAOYSA-L 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 239000006872 mrs medium Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K2035/11—Medicinal preparations comprising living procariotic cells
- A61K2035/115—Probiotics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明提供了副干酪乳杆菌ET‑22提升肠道细菌感染抗性和肠道免疫力的应用。具体地,本发明提供了一种副干酪乳杆菌(Lactobacillus paracasei)在制备用于提升肠道免疫力的组合物中的应用,所述副干酪乳杆菌的保藏编号为CGMCC No.15077。本发明发现该菌株单菌即能够显著提升肠道细菌感染抗性,在肠道系统中抵御致病菌侵入,维持肠道屏蔽功能,和/或预防致病菌引起的腹泻。
Description
技术领域
本发明涉及微生物技术领域,尤其是涉及一种副干酪乳杆菌(Lactobacillusparacasei)ET-22(保藏编号CGMCC No.15077)在提升肠道细菌感染抗性和肠道免疫能力的新应用。
背景技术
肠道上皮细胞是机体抵抗病原菌的第一道屏障。病原菌在上皮细胞上的黏附或侵入,将会刺激肠道上皮细胞产生炎症因子或趋化因子。一些可溶性的介质可以调节肠道免疫系统或者诱发细胞的先天免疫反应。适当的免疫反应及良好的上皮细胞屏障功能将有助于保护宿主免受病原菌的感染。
益生菌是指在摄入足量的数量时,可以对人体健康产生益处的一类活的微生物。益生菌作为肠道微生物组重要的组成成分,对人体健康发挥着不可忽视的重要作用,如营养供给,合成维生素,有助于消化、促进血管新生和肠神经功能。
发明内容
本发明的一个目的在于提供一种副干酪乳杆菌ET-22的新用途。
本发明提供了一株副干酪乳杆菌(Lactobacillus paracasei)的新应用,该菌株本发明中命名为ET-22。该菌株已于2017年12月18日保存于中国微生物菌种保藏管理委员会普通微生物中心(CGMCC)(地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所),分类命名:副干酪乳杆菌(Lactobacillus paracasei);保藏编号CGMCC No.15077。
在本发明中,以肠毒性大肠杆菌(Enterotoxigenic Escherichia coli)ETECH10407和致肠病性大肠杆菌(Enteropathogenic Escherichia coli)EPEC O119作为诱发体外肠道感染的病原菌菌株进行了副干酪乳杆菌ET-22提升肠道免疫力的功能研究。两种类型的E.coli都是常见的致病菌,包含婴儿腹泻、旅行者腹泻、以及在发展中国家或者卫生较差的地区。ETEC H10407是较为成熟、实验常用的模式菌株,也经常用于评价益生菌对于致病菌的黏附能力和炎症信号通路。
本发明的研究发现,副干酪乳杆菌ET-22(即保藏编号为CGMCC No.15077的副干酪乳杆菌)菌株具有抑制肠道病原菌的黏附的作用,能够显著ETEC H1407和EPEC O119对Caco-2细胞的黏附作用,提高肠道屏障完整性,并且具有抑制肠道炎症因子产生的作用,能够缓解由于ETEC H10407引起的炎症反应。
从而,本发明提供了副干酪乳杆菌(Lactobacillus paracasei)在制备用于提升肠道免疫力的组合物中的应用,所述副干酪乳杆菌的保藏编号为CGMCC No.15077。
根据本发明的具体实施方案,本发明的应用中,所述副干酪乳杆菌以活菌和/或死菌的固态或液态菌制剂的形式用于制备所述组合物。
根据本发明的具体实施方案,本发明的应用中,所述提升肠道免疫力包括:提升肠道细菌感染抗性,在肠道系统中抵御致病菌侵入,维持肠道屏蔽功能,和/或预防致病菌引起的腹泻。
根据本发明的具体实施方案,本发明的应用中,所述提升肠道免疫力包括:降低致病菌对肠道上皮细胞的黏附能力,和/或降低致病菌引起的肠道细胞释放炎症因子IL-8和/IP-10。
根据本发明的具体实施方案,本发明的应用中,所述副干酪乳杆菌的应用量为1.0×103CFU~1.0×1012CFU/天,或者以菌体的重量计为0.001μg~1000mg/天。优选地,所述副干酪乳杆菌的应用量为107CFU~1011CFU/天,或者以菌体的重量计为10μg~10mg/天。
根据本发明的具体实施方案,所述组合物可以包括食品组合物、饲料组合物或药品组合物。
根据本发明的具体实施方案,所述组合物可使用于动物或是人类。所述组合物还可包括所属领域中的常规用料组分。例如,对于药物组合物,可包括适量的辅料,所述辅料可以为赋型剂、稀释剂、填充剂、吸收促进剂等。对于食品组合物,本发明的副干酪乳杆菌可以按照现有技术中含副干酪乳杆菌的食品进行生产,所述组合物可根据受施予者的需要,而采用不同形态。例如粉剂、锭剂、造粒、微胶囊、液体制剂等。
在本发明的一具体实施方案中,所述组合物为食品组合物,所述食品可以为液体饮料、固体饮料、口服液、奶制品、片剂或胶囊,例如可以为发酵乳制品(例如发酵乳、风味发酵乳、发酵乳饮料等)、乳酪、含乳饮料、益生菌固体饮料或乳粉等。
在本发明的另一具体实施方案中,所述组合物为饲料组合物。所述饲料组合物中的其他组分可以参照益生菌饲料领域的常规技术进行选择。
在本发明的另一具体实施方案中,所述组合物为药物组合物。所述药物组合物中的其他组分可以参照益生菌药物领域的常规技术进行选择。
综上所述,本发明提供了副干酪乳杆菌ET-22的新用途,该菌具有显著降低致病菌对肠道上皮细胞的黏附能力、提高肠道屏障功能、激活肠道免疫能力的作用,可以用于制备具有抗感染、调节肠道健康和免疫能力的食品、药物及饲料等,具有广泛的应用前景。
附图说明
图1显示了副干酪乳杆菌ET-22的活菌数测定曲线。
图2显示了副干酪乳杆菌ET-22抑制致病性大肠杆菌ETEC H10407对Caco-2的黏附效果(p<0.01).
图3显示了副干酪乳杆菌K56抑制致病性大肠杆菌EPEC O119对Caco-2的黏附效果(p<0.01)。
图4A和图4B显示了副干酪乳杆菌ET-22与母乳低聚糖混合物的组合对肠道屏障的影响。
图5显示了副干酪乳杆菌ET-22与ETEC H10407共培养1h、2h、3h、4h后TEER(Ω.cm2)变化。
图6显示了副干酪乳杆菌ET-22对Caco-2细胞促炎症因子IL-8表达的影响。
图7显示了副干酪乳杆菌ET-22对Caco-2细胞炎症因子IP10的影响。
专利程序的微生物保存:
本发明的副干酪乳杆菌ET-22:
保藏日期:2017年12月18日;
保藏单位:中国微生物菌种保藏管理委员会普通微生物中心(CGMCC);
保藏单位地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所
保藏编号:CGMCC No.15077;
分类命名:副干酪乳杆菌(Lactobacillus paracasei)。
具体实施方式
为了对本发明的技术特征、目的和有益效果有更加清楚的理解,现结合具体实施例及对本发明的技术方案进行以下详细说明,应理解这些实例仅用于说明本发明而不用于限制本发明的范围。实施例中,未注明具体条件的实验方法为所属领域熟知的常规方法和常规条件,或按照仪器制造商所建议的条件。
实施例中所用副干酪乳杆菌ET-22:
本发明的副干酪乳杆菌ET-22已2017年12月18日保存于中国微生物菌种保藏管理委员会普通微生物中心CGMCC(地址:北京市朝阳区北辰西路1号院3号,中国科学院微生物研究所),分类命名:副干酪乳杆菌(Lactobacillus paracasei);保藏编号CGMCCNo.15077。
根据16S rDNA序列分析以及API细菌鉴定系统分析结果来确认ET-22菌株在分类学上的特征。具体如下:
形态学特征:1.于MRS培养液培养时,菌体呈中短杆状,二端呈圆形,通常成链状,偶尔成对出现。2.革兰氏染色阳性杆菌,不生成孢子,不具触酶、氧化酶及运动性,在好氧及厌氧环境均能生长,最适宜的生长温度为37±1℃,属于兼性异质发酵性菌株,葡萄糖代谢时不产生气体。
ET-22菌株的发酵条件为:MRS液体培养基:蛋白胨,10.0g;牛肉膏,10.0g;酵母浸粉,5.0g;葡萄糖,20.0g;磷酸氢二钾,5.0g;柠檬酸氢二铵,2.0g;乙酸钠,5.0g;七水合硫酸镁,0.5g;四水合硫酸锰,0.2g;吐温80,1.0g;琼脂15.0g;蒸馏水1000mL。调整pH至6.2~6.4之间,121℃灭菌15分钟。
副干酪乳杆菌ET-22为微好氧菌,兼性厌氧环境生长较佳,产乳酸,具有耐酸性,可耐受pH值2.5的酸性环境及耐0.4%的胆盐环境4小时,嗜中温菌,生长温度范围在15~45℃,最适生长温度在37℃左右。
实施例中所用副干酪乳杆菌ET-22的活菌数测定:
副干酪乳杆菌ET-22(保藏编号CGMCC No.15077),平板涂布法挑出单菌落,16S鉴定后于甘油管-80℃冷冻保藏。实验前菌株于MRS培养基,37℃培养。生长至对数期离心培养基富集菌体。使用荧光细胞分选法(Flourescence activated cell sorting,FACS)测定活菌数和菌活性,测定结果见图1。菌株在8h进入生长平台期,活菌数变化趋于稳定,在8h活菌数稳定在108cfu/mL范围。本发明各实施例用菌株活菌数分为1×108CFU/mL。
实施例中数据分析:
实验中的所有数据至少重复3次,实验结果表示为平均值±标准差;采用SPSS17.0软件进行数据分析(SPSS,Chicago,IL,USA),显著性分析采用LSD的方法进行单因素方差分析,P-value<0.05被认为有统计学上的显著差异,显著性差异按照:*p<0.05、**p<0.01、***p<0.001、****p<0.0001区分。图的绘制采用GraphPad Prism 5.0。
实施例1.抗黏附能力测定
采用共培养的方法探究副干酪乳杆菌ET-22对EPEC O119是否具有Caco-2黏附抗性。Caco-2细胞接种于24孔板中培养。Caco-2细胞使用PBS缓冲液清洗,菌株和Caco-2细胞共同培养1h。EPEC O119以感染复数(multiplicity of infection,MOI)50:1添加至Caco-2细胞中共同培养1h(37℃),最终活菌数为1×107CFU/mL。以无副干酪乳杆菌ET-22添加的Caco-2组作为阴性对照。使用1mM氧化锌(Zinc Oxide,ZnO)替代副干酪乳杆菌ET-22作为阳性对照组。孵育后,清洗并裂解Caco-2细胞,然后致病菌被接种在琼脂上。在37℃琼脂平板上培养过夜后,数细菌的CFU菌落数以衡量致病菌吸附。数生长中的大肠杆菌菌落数并记录为CFU/mL。与抗粘附测试平行的,将大肠杆菌(终浓度为)107CFU/mL添加到1mL受试物(ET-22菌液)中,并在37℃共培养1小时以测量活性。培养后,从每个样品离心收集大肠杆菌,再悬浮于PBS中,并在琼脂平板上接种。在37℃琼脂平板上培养过夜后,数细菌的CFU菌落数以衡量致病菌吸附。数生长中的大肠杆菌菌落数并记录为CFU/mL。
通过上述以人体肠道细胞Caco-2为模型,本发明证实了副干酪乳杆菌ET-22对肠致病性大肠杆菌EPEC O119具有抑制作用。
在本发明的一些批次的实验中,108CFU/mL浓度的副干酪乳杆菌ET-22对ETECH10407的抑制能力如图2所示,在无副干酪乳杆菌ET-22干预条件下,肠毒性大肠杆菌ETECH10407对Caco-2细胞的黏附数高达3.75×106CFU/mL(6.57log CFU/mL)。而当肠毒性大肠杆菌ETEC H10407和副干酪乳杆菌ET-22共同作用时,黏附的肠致病性大肠杆菌ETECH10407数目为7.67×105CFU/mL(5.88log CFU/mL),抑制率为79.54%。实验结果表明,副干酪乳杆菌ET-22对肠致病性大肠杆菌ETEC H1040具有显著抑制作用(p<0.01)。
在本发明的一些批次的实验中,108CFU/mL浓度的副干酪乳杆菌ET-22对EPECO119抑制能力的实验结果如图3所示。在没有副干酪乳杆菌ET-22的干预条件下,肠致病性大肠杆菌EPEC O119对Caco-2细胞的黏附数高达1.73×106CFU/mL(6.23log CFU/mL)。而当肠致病性大肠杆菌EPEC O119和副干酪乳杆菌ET-22共同作用时,黏附的肠致病性大肠杆菌EPEC O119数目为6.00×105CFU/mL(5.78log CFU/mL),抑制率为65.32%。实验结果表明,副干酪乳杆菌ET-22对肠致病性大肠杆菌EPEC O119具有显著抑制作用(p<0.01)。
上述实验结果表明,副干酪乳杆菌ET-22对肠毒性大肠杆菌ETEC H10407和肠致病性大肠杆菌EPEC O119均具有抑制作用。
实施例2.肠道屏障完整性测试
理想的小肠上皮屏障功能是保护宿主免受致病菌侵入和/或致病菌来源毒素的先决条件。在此研究中,体外的屏障完整性通过测定肠道细胞层的跨表皮的电阻(TEER)体现。为了研究益生菌对于感染的作用,测定了TEER在大肠杆菌感染前和感染后随时间变化的情况。
Caco-2细胞以2×104cell/cm2的浓度被接种到Transwell聚碳酸酯细胞培养插入物中,平均孔径为0.4um,面积为0.33cm2直至完全分化(±1000Ω)。用世界精准仪器购入的EVOM2表皮伏特测量器测量跨上皮细胞电阻(TEER)以衡量屏障完整性。
在测试当天,细胞被冲洗,并在37℃下用不含抗生素和血清、但含有受试物质的培养基中培养1小时。紧接着加入大肠杆菌到受试物质之上(感染倍数MOI为200:1),并培养6小时。在实验开始前(t=-1),受试物质暴露1小时后及添加致病菌前(t=0),并在致病菌接触后1小时、2小时、3小时、4小时和6小时分别测定TEER。在与致病菌接触后单独条件下的TEER值与其各自在t=0时的TEER值相关,且被表述成ΔTEER(Ω.Cm2)。阴性对照(只加入大肠杆菌)与未接触致病菌或受试物质的阳性对照也在实验组别中。所有条件重复测定三次,一些对照组被重复测定6次。
ETEC H10407(MOI=50)攻毒时间达到6h时,空白对照组表现为不理想的TEER数值,表明当攻毒时间达到6小时后,细胞的细胞存活率显著下降,因此,初步确定ETECH10407攻毒时间应控制在4h内。
如图4A和图4B所示,在不同的时间点测试了受试物质对于跨膜电阻的影响,1×108CFU/mL的ET-22可在多个时间点,于一定程度上有提升跨膜电阻TEER值或防止其下降的趋势。图中MixA、MixB、MixC、MixD为母乳低聚糖混合物,当加入ET-22与这些母乳低聚糖的组合物后,跨膜电阻TEER值提升或防止下降的趋势更显著,比空白组效果有提升的趋势。
图5显示了本发明另一批次的实验中108CFU/mL浓度的副干酪乳杆菌ET-22与ETECH10407共培养1h、2h、3h、4h后TEER(Ω.cm2)变化。由图5可知,在添加ET-22后,跨膜电阻增加。处理4h后,ET-22组别跨膜电阻以时间依赖方式降低,在t=2h、t=3h时,与ETEC H10407组别相比,具有显著差异(p<0.01)。表明副干酪乳杆菌ET-22的干预缓解了由于ETECH10407引起的肠道细胞屏障的完整性破坏。
实施例3.免疫调节能力测定
副干酪乳杆菌ET-22的免疫调节能力是基于是否能降低ETCT H10407 Caco-2细胞诱发的IL-8、IP-10的产生。将Caco-2细胞在96孔板养到适合的丰度。在实验最初,用不含抗生素的培养基冲洗细胞一次。将单层细胞与受试物质在37℃下用不含抗生素的培养基中共培养1小时,重复三次。加入大肠杆菌刺激细胞(MOI 200:1)。在1小时培养后,单层细胞与致病菌共培养,并用含有受试物质和50μg/mL庆大霉素的培养液冲洗和培养过夜。作为空白对照(Blank),只用了培养液而没用大肠杆菌刺激。用大肠杆菌刺激但没用受试物质的培养液被用作大肠杆菌应答的对照。此外,作为Caco-2细胞应答的对照,用含有Rec TNFα(10ng/mL)以及Rec IFNγ(5ng/mL)(均从英国阿宾顿的R&D systems购入)的混合物培养液刺激细胞。刺激24小时候收集上清液并储存于-20℃。按照生产商的使用指导,用Bio-Plex试剂盒(美国加州BioRad公司)测试IL-8、IP-10。
108CFU/mL浓度的副干酪乳杆菌ET-22对Caco-2细胞炎症因子IL-8的影响的实验结果参见图6。108CFU/mL浓度的副干酪乳杆菌ET-22对Caco-2细胞炎症因子IP10的影响的实验结果参见图7。由图6可知,ETEC H10407胁迫后,细胞培养液中的IL-8含量从2.62±0.44pg/mL提升至473.84±21.9pg/mL,加入ET-22处理后,IL-8表达回复至17.09±1.89pg/mL,表明副干酪乳杆菌ET-22对ETEC H10407诱导的IL-8含量增加具有显著抑制作用(p<0.001)。由图7可知,ETEC H10407胁迫后后,细胞培养液中的IP10含量从5±0.00pg/mL提升至1454.08±193.31pg/mL,加入ET-22处理后,IP10表达回复至10.94±8.41pg/mL,表明副干酪乳杆菌ET-22对ETEC H10407诱导的IP10含量增加具有显著抑制作用(p<0.001)。实验结果表明副干酪乳杆菌ET-22具有抑制炎症因IL-8、IP10产生,显著抑制ETEC 10407引起的炎症反应(p<0.001),进一步说明ET-22具有一定程度降低ETEC 10407引起炎症反应的潜力。
以上研究结果证实:副干酪乳杆菌ET-22能够显著ETEC H1407和EPEC O119对Caco-2细胞的黏附作用,缓解由于ETEC H10407引起的炎症反应。表明副干酪乳杆菌ET-22对于预防婴儿腹泻、旅行者腹泻、肠道炎症等具有良好的潜力。
Claims (1)
1. 一种副干酪乳杆菌 (Lactobacillus paracasei)在制备用于提升肠道免疫力的组合物中的应用,所述副干酪乳杆菌的保藏编号为CGMCC No. 15077,其中,所述提升肠道免疫力为:降低肠毒性大肠杆菌ETEC H10407引起的肠道细胞释放炎症因子IL-8和IP-10。
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/096959 WO2022110727A1 (zh) | 2019-11-29 | 2021-05-28 | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 |
EP21896237.1A EP4252554A1 (en) | 2019-11-29 | 2021-05-28 | Application of lactobacillus paracasei et-22 in improving intestinal bacterial infection resistance and intestinal immunity |
US18/254,989 US20240091283A1 (en) | 2019-11-29 | 2021-05-28 | Application of Lactobacillus Paracasei ET-22 In Improving Intestinal Bacterial Infection Resistance and Intestinal Immunity |
AU2021388477A AU2021388477A1 (en) | 2019-11-29 | 2021-05-28 | Use of Lactobacillus paracasei ET-22 for enhancing resistance of intestinal tract to bacterial infection and improving intestinal immunity |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911203917 | 2019-11-29 | ||
CN2019112039170 | 2019-11-29 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112869169A CN112869169A (zh) | 2021-06-01 |
CN112869169B true CN112869169B (zh) | 2023-07-18 |
Family
ID=76043142
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011369722.6A Active CN112869170B (zh) | 2019-11-29 | 2020-11-30 | 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用 |
CN202011369708.6A Active CN112869169B (zh) | 2019-11-29 | 2020-11-30 | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011369722.6A Active CN112869170B (zh) | 2019-11-29 | 2020-11-30 | 可提高胃肠道免疫能力的益生菌益生元营养组合物及应用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20240091283A1 (zh) |
EP (1) | EP4252554A1 (zh) |
CN (2) | CN112869170B (zh) |
AU (1) | AU2021388477A1 (zh) |
WO (1) | WO2022110727A1 (zh) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117860789A (zh) * | 2020-11-16 | 2024-04-12 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌k56在抗衰老、提高先天免疫方面的新应用 |
CN114504599A (zh) * | 2020-11-16 | 2022-05-17 | 内蒙古伊利实业集团股份有限公司 | 副干酪乳杆菌et-22在抗衰老、提高先天免疫方面的新应用 |
CN113396974B (zh) * | 2021-07-01 | 2023-01-24 | 光明乳业股份有限公司 | 一种副干酪乳杆菌在制备发酵乳制品中的用途在2型糖尿病中的应用 |
CN113396976B (zh) * | 2021-07-01 | 2023-01-24 | 光明乳业股份有限公司 | 一种副干酪乳杆菌发酵乳(粉)及其制备方法与在改善肠屏障受损中的应用 |
CN116195740A (zh) * | 2021-11-30 | 2023-06-02 | 内蒙古伊利实业集团股份有限公司 | 可提升生物体对金黄色葡萄球菌感染抵御能力的益生元与益生菌组合物 |
CN117586926B (zh) * | 2024-01-18 | 2024-04-16 | 东北农业大学 | 副干酪乳杆菌lp-116、lp-116后生元组合物及其制备方法与应用 |
CN117603885B (zh) * | 2024-01-18 | 2024-04-05 | 东北农业大学 | 一种副干酪乳杆菌lp-116及其在制备调节肠道屏障受损产品中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL145080A0 (en) * | 1999-03-11 | 2002-06-30 | Nestle Sa | Lactobacillus strains capable of preventing diarrhoea caused by pathogenic bacteria and rotaviruses |
PE20030283A1 (es) * | 2001-07-26 | 2003-05-01 | Alimentary Health Ltd | Cepas de lactobacillus casei |
WO2012029367A1 (ja) * | 2010-08-31 | 2012-03-08 | 国立大学法人新潟大学 | 腸管免疫調整剤 |
CA2822500C (en) * | 2010-12-31 | 2022-07-26 | Abbott Laboratories | Human milk oligosaccharides to promote growth of beneficial bacteria |
WO2012177556A2 (en) * | 2011-06-20 | 2012-12-27 | H.J. Heinz Company | Probiotic compositions and methods |
BR112014004772A2 (pt) * | 2011-08-29 | 2017-03-21 | Abbott Lab | oligossacarídeos do leite humano para evitar danos e/ou promover a cura do trato gastrointestinal |
CN104894021B (zh) * | 2015-06-03 | 2018-02-09 | 宜兰食品工业股份有限公司 | 一种副干酪乳杆菌及其应用 |
TWI592487B (zh) * | 2016-10-05 | 2017-07-21 | 益福生醫股份有限公司 | 新穎副乾酪乳桿菌副乾酪亞種k56 |
CN108373984A (zh) * | 2018-04-09 | 2018-08-07 | 北京博锦元生物科技有限公司 | 一种副干酪乳杆菌及其应用 |
CN110964658B (zh) * | 2018-09-30 | 2021-07-06 | 内蒙古伊利实业集团股份有限公司 | 一种具有免疫调节功能的副干酪乳杆菌et-22 |
CN110893195B (zh) * | 2019-09-30 | 2023-03-14 | 内蒙古伊利实业集团股份有限公司 | 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22 |
-
2020
- 2020-11-30 CN CN202011369722.6A patent/CN112869170B/zh active Active
- 2020-11-30 CN CN202011369708.6A patent/CN112869169B/zh active Active
-
2021
- 2021-05-28 AU AU2021388477A patent/AU2021388477A1/en active Pending
- 2021-05-28 WO PCT/CN2021/096959 patent/WO2022110727A1/zh unknown
- 2021-05-28 EP EP21896237.1A patent/EP4252554A1/en active Pending
- 2021-05-28 US US18/254,989 patent/US20240091283A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN112869170A (zh) | 2021-06-01 |
WO2022110727A1 (zh) | 2022-06-02 |
CN112869169A (zh) | 2021-06-01 |
EP4252554A1 (en) | 2023-10-04 |
CN112869170B (zh) | 2023-05-23 |
US20240091283A1 (en) | 2024-03-21 |
AU2021388477A1 (en) | 2023-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112869169B (zh) | 副干酪乳杆菌et-22提升肠道细菌感染抗性和肠道免疫力的应用 | |
WO2021114658A1 (zh) | 动物双歧杆菌乳亚种i797、其分离纯化方法及应用 | |
WO2022110725A1 (zh) | 乳双歧杆菌bl-99提升肠道细菌感染抗性和肠道免疫力的应用 | |
WO2022036822A1 (zh) | 一株具有免疫调节作用的鼠李糖乳杆菌及其应用 | |
CN112869167A (zh) | 副干酪乳杆菌k56提升肠道细菌感染抗性和肠道免疫力的应用 | |
CN112515170B (zh) | 提高胃肠道免疫能力的乳双歧杆菌与益生元组合物及应用 | |
WO2022236935A1 (zh) | 一种具有抑制奇异变形杆菌生长作用的益生菌及其发酵液和应用 | |
CN110564638A (zh) | 一株具有益生特性的罗伊氏乳杆菌及其用途 | |
CN113913322A (zh) | 乳双歧杆菌BLa80在缓解腹泻和提升肠道免疫能力中的应用 | |
CN113249244B (zh) | 一种拮抗咽炎致病菌乙型溶血性链球菌的副干酪乳杆菌 | |
EP3092320B1 (en) | New strains of the genus lactobacillus and use thereof | |
US11786568B2 (en) | Strain of caucasus yoghurt lactobacillus MSR101 and use thereof | |
WO2022110281A1 (zh) | 两歧双歧杆菌i771、其分离纯化方法及应用 | |
CN114568516A (zh) | 包含长双歧杆菌婴儿亚种与母乳低聚糖的组合物及其应用 | |
CN113712207B (zh) | 提高胃肠道免疫能力的益生菌益生元组合物及其应用 | |
CN102399728B (zh) | 一种乳酸杆菌及其发酵方法 | |
CN114990030A (zh) | 嗜酸乳杆菌la18及其在制备调节肠道菌群或免疫调节的产品方面的应用 | |
KR100786364B1 (ko) | 신규한 면역활성능이 있는 락토바실러스 파라카제이bfi46과 락토바실러스 파라카제이 afj88 균주 | |
US20230310523A1 (en) | Use of lactic acid bacteria or fermentation product thereof for maintaining or improving gastrointestinal condition | |
CN114395514B (zh) | 一株嗜酸乳杆菌、菌剂及其应用 | |
CN116019842B (zh) | 嗜酸乳杆菌la85的抑菌新用途及其在制备缓解eiec腹泻的药物方面的用途 | |
CN114634884B (zh) | 长双歧杆菌婴儿亚种gb-1496及其提升肠道细菌感染抗性和肠道免疫力的应用 | |
CN115044504B (zh) | 一株粪肠球菌yz-1及其益生性应用 | |
KR101279804B1 (ko) | 스트렙토코커스 마세도니커스 lc743 균주를 함유하는 발효유 및 그 제조방법 | |
CN117683670A (zh) | 一种植物乳植杆菌fmbl l23036 cnn、酸奶发酵剂、酸奶及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |